FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Xenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.42), $0.06 worse than the analyst estimate of ($0.36).
Dr. Simon Pimstone, Xenons Chief Executive Officer, said, We continue to make significant progress advancing our robust, novel pipeline comprised of neurology-focused product candidates, including XEN496, XEN1101, XEN901,... More


